Both prospective and retrospective analyses in large Phase I, II and III trials in NSCLC and melanoma patients have demonstrated the association between tumor PD-L1 expression and response to anti-PD-1 agents [17, 98]. This evidence concerns the gene PDCD1 and neoplasm.